Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy

Related Clinical Trial
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy and Metachromatic Leukodystrophy SMART-ALD – A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD) Quality of Life in Women With X-linked Adrenoleukodystrophy A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT) Plasma Exchange With Albumin in AMN Patients Stem Cell Transplant for Inborn Errors of Metabolism Human Placental-Derived Stem Cell Transplantation Precision Exercise in Children With Malignant Hemopathies Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy MD1003-AMN MD1003 in Adrenomyeloneuropathy A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD) A Clinical Trial for AMN: Validation of Biomarkers of Oxidative Stress, Efficacy and Safety of a Mixture of Antioxidants Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children Early Diagnosis Of Childhood Cerebral ALD Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children HSCT for High Risk Inherited Inborn Errors Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD) UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) A Phase III Trial of Lorenzo’s Oil in Adrenomyeloneuropathy Lentiviral Gene Therapy for X-ALD MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD) Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Newborn Screening for Adrenoleukodystrophy A Study to Prospectively Assess Disease Progression in Male Children With X-ALD Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy Expanded Access for Lorenzo’s Oil (GTO/GTE) in Adrenoleukodystrophy Minnesota Adrenoleukodystrophy Registry Study (MARS) and Biobank A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Effect of Glycerol Trierucate on Clinical Course of Adrenoleukodystrophy

Brief Title

Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy

Official Title

Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy: a Phase II, Single-arm, Multicentric Clinical Trial

Brief Summary

      X-linked adrenoleukodystrophy is a rare, demyelinating and neurodegenerative disorder, due to
      loss of function of a fatty acid transporter, the peroxisomal ABCD1 protein. Its more
      frequent phenotype, the adrenomyeloneuropathy in adults, is characterized by axonal
      degeneration in spinal cord, spastic paraparesis and a disabling peripheral neuropathy.
      Actually, there is no efficient treatment for the disease. The work of the researchers in the
      last twelve years dissecting the physiopathological basis of the disorder has uncovered an
      involvement of the early oxidative stress in the neurodegenerative cascade and mitocondrial
      depletion. In a preclinical trial they have observed that pioglitazone, a PPARγ/PGC-1α axis
      metabolic activator with immunomodulatory, anti-inflammatory and antioxidant response
      regulator properties, efficiently reverse the clinical symptoms and the axonal degeneration
      in the mouse model for the disease and normalize stress and mitochondrial depletion
      biomarkers.

      The researchers will test the effectiveness of the drug in terms of motor function and
      correction of oxidative damage markers in proteins and DNA and inflammation markers in an
      open trial. Fifteen-twenty patients will be included and clinically explored and assessed in
      the HU of Bellvitge and the HU of Donostia using clinical scales for spasticity, evoked
      potentials, electroneurinograms and cranial RMN. The information will be collected in a data
      base that will be of great value to improve the present attention and the future follow-up of
      the patients and to facilitate their inclusion in therapeutic randomized, double blind,
      against placebo, multicentric and international clinical trials.
    

Detailed Description

      Proof of concept for this trial is provided by the results of biochemical, neuropathological
      and motor effects of pioglitazone in two mouse models of AMN. Pioglitazone was given orally
      (9 mg/kg/day) for two months in both models.

      The Abcd1-null mouse model already shows at 3,5 months biochemical signs oxidative stress
      that increase with time and are then associated with energy homeostasis alterations, although
      first clinical signs of AMN-i.e. axonopathy and locomotor impairment-appear at 20 months. In
      these mice, there are mitochondrial anomalies, decreased levels of PGC-1α which is a master
      regulator of mitochondrial biogenesis, and decreased levels and activity of SIRT1α, which
      activates PGC-1α.

      The Abcd1-null mouse can be considered as a "AMN-like" model, because of the absence of
      demyelinating lesions in brain and spinal cord, the presence of non-inflammatory
      ''dying-back'' axonopathy in peripheral nerves and spinal cord and its late-onset motor
      deficits that all are hallmarks of AMN in X-ALD patients. This model was used to assess the
      efficacy of pioglitazone on several biochemical markers in the spinal cord of Abcd1-null mice
      (N=12), using comparisons with placebo-¬treated Abcd1-null mice (N=12) or wild-type mice
      (N=12).

      In Abcd1-null mice treated with pioglitazone at 10,5 months of age and studied at 12 months
      (1,5 months following the beginning of the ongoing treatment), mitochondrial anomalies were
      corrected to the level of wild type control mice. Indeed, mitochondrial DNA and protein
      (including PGC-1α, NRF1 and TFAM) levels were corrected; as well as mitochondrial metabolism,
      as assessed by pyruvate kinase activity, ATP and NAD+ concentrations. Pioglitazone had no
      effect on SIRT1 expression (mRNA and protein levels). However, pioglitazone significantly
      lowered the carbonylation of SIRT1 protein, which presumably accounts for the observed rescue
      of SIRT1 activity.

      In these mice treated with pioglitazone, oxidative lesions in the spinal cord were reversed.
      Studied oxidative stress biomarkers included markers of oxidative lesions to proteins (GSA,
      AASA), lipids (MDAL) and carbohydrates (CEL). Additionally, the activity and concentration
      level of antioxidant enzymes GPX1, which were increased in untreated Abcd1-null mice, but not
      SOD2, was normalized to the level of wild type mice.

      The second mouse model is the double knockouts (DKO) in which both Abcd1 and Abcd2
      transporters are inactivated. The Abcd1-/Abcd2-/-DKO exhibits greater VLCFA accumulation in
      spinal cord (Pujol et al., 2004), higher levels of oxidative damage to proteins, and a more
      severe AMN-¬like pathology, with earlier onset of motor impairment than the single Abcd1-null
      mouse (12 months in the DKO compared to 20 months in Abcd1-null mice). Efficacy of
      pioglitazone at the motor and neuropathologic levels was studied in 17 Abcd1-/Abcd2-/-mice
      comparing them with placebo-treated Abcd1-/Abcd2-/-mice (N=17) and wild-type mice (N=25).

      In Abcd1-/Abcd2-/-mice treated with pioglitazone at 13 months of age and studied at 15 or 17
      months (treatment duration of 2 to 4 months), axonal degeneration was prevented, as shown by
      the normalization to the control level of number of APP or synaptophysin positive axons.

      Also, pioglitazone arrested the progression of locomotor deficits in these mice, as assessed
      by the treadmill test and the bar-cross test. Indeed, the locomotor performances of
      pioglitazone DKO after four months of treatment mice reached the performances of the
      controls.

      Overall, these studies show the efficacy of treatment with pioglitazone in "AMN-like mice
      "and provide a strong rationale for conducting a preliminary open clinical trial with
      pioglitazone in AMN patients.
    

Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

2 Minute Walk Test (2MWT)

Secondary Outcome

 Timed Up and Go (TUG) test

Condition

Adrenomyeloneuropathy

Intervention

Pioglitazone

Study Arms / Comparison Groups

 XAMNPIO
Description:  Pioglitazone 15 mg tablets 2/day during 2 years

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

18

Start Date

January 2016

Completion Date

July 2019

Primary Completion Date

March 2019

Eligibility Criteria

        Inclusion Criteria:

          -  Clinical signs of AMN with at least pyramidal signs in the lower limbs and
             difficulties to run.

          -  Presence of motor deficit according to the EDSS scale

          -  Ability to perform the 2MWT

          -  Normal brain MRI or brain MRI showing abnormalities that can be observed in AMN
             patients without cerebral form of X-ALD with a maximum Loes score of 4

          -  Ejection fraction > 50% at echocardiogram

          -  Normal electrocardiogram

          -  Normal urine cytology

          -  Normal liver function, as assessed by plasma ASAT, ALAT, PAL, γGT, bilirubin measures
             (≤2.5-fold normal values)

          -  Normal kidney function as assessed by plasma urea, creatinin (≤ 2-fold normal values)

          -  Appropriate steroid replacement if adrenal insufficiency is present

          -  Informed consent

          -  Affiliated to the Spanish Public Health System

        Exclusion Criteria:

          -  Gadolinium enhancement on T1 sequence of any abnormal hypersignal of white matter,
             including myelinated pyramidal tracts, visible at brain MRI on FLAIR sequences

          -  Brain MRI abnormalities of the "AMN type" with a Loes score > 4

          -  Any abnormal hypersignal of white matter visible on FLAIR sequences other than of "AMN
             type" and related to X-ALD

          -  Patients taking pioglitazone or another glitazone during the past 6 months

          -  Diabetic patients (type I or II)

          -  Fasting blood glucose > 125 mg/L

          -  Glycosylated hemoglobin > 6%

          -  History of heart failure

          -  Heart failure (NYHA III to IV) or ejection fraction ≤ 50%

          -  History of cardiac disease

          -  [Hemoglobin] < 13g/dl in males, <12 g/dl in women

          -  Absolute neutrophil count (ANC) <1500 cells/mm3

          -  Platelet count <100,000 cells/mm3

          -  Significant peripheral edema (2+ or more on the Assessment Chart for Pitting Edema) of
             the extremities of any etiology

          -  Any evolutive malignancy during the last five years

          -  Prior or current bladder cancer

          -  Smokers (one pack/ day or more for at least 20 years), current or former

          -  Women with history of osteoporosis

          -  Menopaused woman with T-score < -2.5 on osteodensitometry measurement

          -  Any evolutive medical disease other than AMN

          -  Any psychiatric disease

          -  Pregnant or breastfeeding woman

          -  Either no pre-menopaused woman or no menopaused woman not taking any contraceptive
             method

          -  Hereditary intolerance to galatose, or malabsorption of glucose or galactose due the
             presence of monohydrated lactose.

          -  Hypersensibility to the active substance or to galactose (excipient)

          -  Concomitant treatment with cytochrome P450 CYP 2C8 inhibitors (e.g. gemfibrozil) or
             inducers (e.g. rifampicin)

          -  Taking of either vitamin A, E or lipoic acid during the past 3 months

          -  Contraindications for MRI procedure such as subjects with paramagnetic materials in
             the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants

          -  Present participation to another therapeutic clinical trial for ALD

          -  Not easily contactable by the investigator in case of emergency or not capable to call
             the investigator

          -  Gross hematuria of unknown origin
      

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

, , 

Location Countries

Spain

Location Countries

Spain

Administrative Informations


NCT ID

NCT03864523

Organization ID

XAMNPIOAP2011


Responsible Party

Sponsor

Study Sponsor

Onofre, Aurora Pujol, M.D.

Collaborators

 Instituto de Salud Carlos III

Study Sponsor

, , 


Verification Date

March 2019